PMID- 35117685
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220501
IS  - 2219-6803 (Electronic)
IS  - 2218-676X (Print)
IS  - 2218-676X (Linking)
VI  - 9
IP  - 5
DP  - 2020 May
TI  - Drug-eluting beads-transcatheter arterial chemoembolization with or without 
      iodine-125 treatment is effective and tolerable in treating advanced non-small 
      cell lung cancer patients: a pilot study.
PG  - 3191-3202
LID - 10.21037/tcr.2020.03.64 [doi]
AB  - BACKGROUND: This study aimed to explore the efficacy and safety of drug-eluting 
      beads-transcatheter arterial chemoembolization (DEB-TACE) with or without 
      iodine-125 ((125)I) seed implantation in treating advanced non-small cell lung 
      cancer (NSCLC) patients. METHODS: A total of 25 advanced NSCLC patients underwent 
      DEB-TACE were consecutively enrolled, among which 17 cases also received (125)I 
      seed implantation post DEB-TACE treatment. Treatment response, overall survival 
      (OS), biochemical indexes and safety profiles were recorded and analyzed. 
      RESULTS: Zero (0.0%), 13 (54.2%), 9 (37.5%) and 2 (8.3%) patients realized 
      complete response (CR), partial response (PR), stable disease (SD) and 
      progression disease (PD) respectively, and the objective response rate (ORR) and 
      disease control rate (DCR) were 54.2% and 91.7%. The median OS was 12.6 (95% CI: 
      7.8-17.5) months. No difference of treatment response or OS was observed between 
      DEB-TACE treatment alone and DEB-TACE plus (125)I seed implantation. Predictive 
      factors analysis revealed that tumor size correlated with worse OS. Besides, 
      chest distress grade and dyspnea grade were decreased after DEB-TACE procedure, 
      while clinical symptoms were not changed after (125)I seed implantation. The 
      common adverse events (AEs) were fever (32.0%), pain (12.0%) by DEB-TACE 
      treatment, and common AE was pain (26.7%) by (125)I seed implantation. 
      CONCLUSIONS: DEB-TACE with or without (125)I seed implantation is effective and 
      tolerable in treating advanced NSCLC patients.
CI  - 2020 Translational Cancer Research. All rights reserved.
FAU - Zhao, Zhongwei
AU  - Zhao Z
AD  - Key Laboratory of Imaging Diagnosis and Minimally Invasive Intervention Research, 
      Zhejiang University Lishui Hospital, The Fifth Affiliated Hospital of Wenzhou 
      Medical University, Lishui Central Hospital, Lishui 323000, China.
AD  - Department of Interventional Radiology, Zhejiang University Lishui Hospital, The 
      Fifth Affiliated Hospital of Wenzhou Medical University, Lishui Central Hospital, 
      Lishui 323000, China.
FAU - Tu, Jianfei
AU  - Tu J
AD  - Key Laboratory of Imaging Diagnosis and Minimally Invasive Intervention Research, 
      Zhejiang University Lishui Hospital, The Fifth Affiliated Hospital of Wenzhou 
      Medical University, Lishui Central Hospital, Lishui 323000, China.
AD  - Department of Interventional Radiology, Zhejiang University Lishui Hospital, The 
      Fifth Affiliated Hospital of Wenzhou Medical University, Lishui Central Hospital, 
      Lishui 323000, China.
FAU - Fan, Xiaoxi
AU  - Fan X
AD  - Key Laboratory of Imaging Diagnosis and Minimally Invasive Intervention Research, 
      Zhejiang University Lishui Hospital, The Fifth Affiliated Hospital of Wenzhou 
      Medical University, Lishui Central Hospital, Lishui 323000, China.
AD  - Department of Interventional Radiology, Zhejiang University Lishui Hospital, The 
      Fifth Affiliated Hospital of Wenzhou Medical University, Lishui Central Hospital, 
      Lishui 323000, China.
FAU - Song, Jingjing
AU  - Song J
AD  - Key Laboratory of Imaging Diagnosis and Minimally Invasive Intervention Research, 
      Zhejiang University Lishui Hospital, The Fifth Affiliated Hospital of Wenzhou 
      Medical University, Lishui Central Hospital, Lishui 323000, China.
AD  - Department of Interventional Radiology, Zhejiang University Lishui Hospital, The 
      Fifth Affiliated Hospital of Wenzhou Medical University, Lishui Central Hospital, 
      Lishui 323000, China.
FAU - Wu, Fazong
AU  - Wu F
AD  - Key Laboratory of Imaging Diagnosis and Minimally Invasive Intervention Research, 
      Zhejiang University Lishui Hospital, The Fifth Affiliated Hospital of Wenzhou 
      Medical University, Lishui Central Hospital, Lishui 323000, China.
AD  - Department of Interventional Radiology, Zhejiang University Lishui Hospital, The 
      Fifth Affiliated Hospital of Wenzhou Medical University, Lishui Central Hospital, 
      Lishui 323000, China.
FAU - Ying, Xihui
AU  - Ying X
AD  - Key Laboratory of Imaging Diagnosis and Minimally Invasive Intervention Research, 
      Zhejiang University Lishui Hospital, The Fifth Affiliated Hospital of Wenzhou 
      Medical University, Lishui Central Hospital, Lishui 323000, China.
AD  - Department of Interventional Radiology, Zhejiang University Lishui Hospital, The 
      Fifth Affiliated Hospital of Wenzhou Medical University, Lishui Central Hospital, 
      Lishui 323000, China.
FAU - Mao, Jianting
AU  - Mao J
AD  - Key Laboratory of Imaging Diagnosis and Minimally Invasive Intervention Research, 
      Zhejiang University Lishui Hospital, The Fifth Affiliated Hospital of Wenzhou 
      Medical University, Lishui Central Hospital, Lishui 323000, China.
AD  - Department of Interventional Radiology, Zhejiang University Lishui Hospital, The 
      Fifth Affiliated Hospital of Wenzhou Medical University, Lishui Central Hospital, 
      Lishui 323000, China.
FAU - Ji, Jiansong
AU  - Ji J
AD  - Key Laboratory of Imaging Diagnosis and Minimally Invasive Intervention Research, 
      Zhejiang University Lishui Hospital, The Fifth Affiliated Hospital of Wenzhou 
      Medical University, Lishui Central Hospital, Lishui 323000, China.
AD  - Department of Interventional Radiology, Zhejiang University Lishui Hospital, The 
      Fifth Affiliated Hospital of Wenzhou Medical University, Lishui Central Hospital, 
      Lishui 323000, China.
LA  - eng
PT  - Journal Article
PL  - China
TA  - Transl Cancer Res
JT  - Translational cancer research
JID - 101585958
PMC - PMC8798642
OTO - NOTNLM
OT  - Drug-eluting beads-transcatheter arterial chemoembolization (DEB-TACE)
OT  - non-small cell lung cancer (NSCLC)
OT  - overall survival (OS)
OT  - safety profiles
OT  - treatment response
COIS- Conflicts of Interest: The authors have no conflicts of interest to declare.
EDAT- 2020/05/01 00:00
MHDA- 2020/05/01 00:01
PMCR- 2020/05/01
CRDT- 2022/02/04 05:51
PHST- 2019/08/14 00:00 [received]
PHST- 2020/03/10 00:00 [accepted]
PHST- 2022/02/04 05:51 [entrez]
PHST- 2020/05/01 00:00 [pubmed]
PHST- 2020/05/01 00:01 [medline]
PHST- 2020/05/01 00:00 [pmc-release]
AID - tcr-09-05-3191 [pii]
AID - 10.21037/tcr.2020.03.64 [doi]
PST - ppublish
SO  - Transl Cancer Res. 2020 May;9(5):3191-3202. doi: 10.21037/tcr.2020.03.64.